Reducing high-dose opioid therapy does not worsen pain severity, functional ability, or aberrant drug-related behaviors in chronic pain patients when concurrent biopsychosocial services are offered.
Sometimes, chronic pain patients intentionally magnify or downplay their physical and mental symptoms during office visits. Despite that fact, little attention in the clinical setting is paid to underlying motives for positively or negatively biased self-reports.
Even if a chronic pain patient had been taking opioid medications exactly as prescribed, it would still be possible for the patient to experience negative cognitive and emotional responses to dose tapering that could amplify sensory pain and lead to opioid addiction.
In light of the fact that many physicians continue to rely on observational analysis and patient self-reporting to monitor opioid addiction or misuse, results from a scientific poster reinforced the benefits of routine urine drug testing in improving compliance with prescribed opioid medications and ultimately enhancing pain care.
Results of a long-term study indicate that when both parents smoke, children’s absorption of secondhand smoke leads to increased artery wall thickness.
A 40-member coalition partly comprised of physician experts on opioid addiction treatment and overdose prevention is asking the US Food and Drug Administration to rescind its approval of extended-release Zohydro (hydrocodone bitratrate), given the drug’s perceived dangers to the public.